Mescaline-FLY

Mescaline-FLY is not known to have been tested in humans, and hence it is unknown whether it produces psychedelic effects in humans. However, based on its lack of psychedelic-like effects in animals, it may not be expected to be hallucinogenic in humans.

Pharmacodynamics

Mescaline-FLY shows affinity for the serotonin 5-HT₂ receptors. Its affinities (K_i) were 335 to 4,443 nM for the serotonin 5-HT_2A receptor, 205 to 302 nM for the serotonin 5-HT_2B receptor, and 61.5 to 654 nM for the serotonin 5-HT_2C receptor. The affinity of mescaline-FLY for the serotonin 5-HT_2A receptor was only slightly higher than that of mescaline, whereas it showed several-fold higher affinity for the serotonin 5-HT_2C receptor and about 2-fold higher affinity for the serotonin 5-HT_2B receptor compared to mescaline. In a subsequent study, at the serotonin 5-HT_2A receptor, its affinity (K_0.5) was 243 nM and its EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) was 3,470 nM (57%), relative to respective values for mescaline of 801 nM and 2,700 nM (88%). Hence, whereas mescaline is a full agonist of the serotonin 5-HT_2A receptor, mescaline-FLY is a moderate-efficacy partial agonist of the receptor.

The drug failed to substitute for LSD in rodent drug discrimination tests, producing a maximum substitution of 29% at a dose of 55.2 μmol/kg, whereas mescaline fully substituted for LSD with an ED₅₀Tooltip median effective dose of 33.5 μmol/kg. The lack of substitution with mescaline-FLY is in notable contrast to findings with other FLY drugs, such as 2C-B-FLY, DOB-FLY, and Bromo-DragonFLY.

Mescaline-FLY was first described in the scientific literature by the lab of David E. Nichols and colleagues by 1995.

Legal status

Canada

Mescaline-FLY is not a controlled substance in Canada as of 2025.

United States

Mescaline-FLY is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.